Medication info

Sitameron Tablets 50/850 Milligrams

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
PTP - 28 tablets/box[(14 tablets/PTP*2)], PTP - 56 tablets/box[(14 tablets/PTP*4)]
Approval status
Approval withdrawn

MFDS item code 201505845 · Approved 2015.08.20

This product's status changed to Approval withdrawn on 2023.08.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control disorders
View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It is mainly administered as an adjunct therapy when control is difficult through diet and exercise alone. It is effective when starting diabetes medication or when blood sugar control with monotherapy is inadequate. Additionally, this medication can replace or be used in conjunction with metformin or sitagliptin monotherapy when blood sugar control is difficult. It can be used together with other diabetes medications such as sulfonylureas, thiazolidinediones, and insulin when blood sugar cannot be sufficiently controlled, thus improving blood sugar control in various therapeutic situations.

Dosage and Administration

Adult dosage

In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication is a diabetes treatment containing two components that help control blood sugar levels. When taking this medication, caution must be taken for hypersensitivity reactions. Rarely, severe allergic reactions may occur, so if symptoms such as rash, hives, or difficulty breathing arise, immediately stop taking the drug and inform a healthcare professional. Pancreatitis, an inflammation of the pancreas, may develop; therefore, if symptoms such as abdominal pain, nausea, vomiting, or fever appear after taking this medication, consult a doctor immediately. One of the components in this medication may pose risks to patients with renal dysfunction; therefore, patients with impaired kidney function or those with heart failure, acute myocardial infarction, or severe infections should not take it. Additionally, this medication should be discontinued before tests involving radioiodine contrast agents and should only be resumed after confirming normal kidney function post-examination. Women who are pregnant or may become pregnant, as well as breastfeeding women, are advised not to take this medication. Hypoglycemia may occur while taking this medication, so extra caution should be taken when skipping meals or engaging in vigorous exercise, as the risk of hypoglycemia can be heightened when taken with other blood sugar-lowering agents. This medication should also be administered with caution to patients with impaired liver function, and regular monitoring of liver and kidney function tests is required. Alcohol consumption can increase the risk of a serious side effect known as lactic acidosis, so excessive drinking should be avoided while on this medication. In cases of surgeries, except for minor surgeries where there are no restrictions on food and fluid intake, this medication should be stopped 48 hours prior to surgery and can be resumed after confirming that kidney function has recuperated post-surgery. While taking this medication, it is important to adhere to a dietary regimen and regular exercise, as well as routinely check blood sugar and kidney function. In case of overdose, symptomatic treatment such as removing the medication from the gastrointestinal tract will be conducted, and since this medication can be partially removed by dialysis, dialysis treatment may be beneficial if necessary. If symptoms such as skin blisters or severe joint pain and muscle pain appear during the course of treatment, inform the doctor immediately. Elderly patients may experience diminished kidney function, so dose adjustments and regular monitoring of kidney function are necessary. Finally, this medication can interact with other drugs, so if you are taking any other medications, you must inform your healthcare provider.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe joint pain with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disorders
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the effectiveness and safety of the medication for a long time.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

PTP - 28 tablets/box[(14 tablets/PTP*2)], PTP - 56 tablets/box[(14 tablets/PTP*4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.